Our lastest news on Orsiro and Orsiro Mission DES

22
March
2021
| 11:13 Europe/Amsterdam

Superioridad del DES Orsiro frente al DES Xience confirmada en pacientes STEMI

En el estudio clínico BIOSTEMI, concebido para demostrar superioridad, se confirma que Orsiro es un stent farmacoactivo (DES, por sus siglas en inglés) superior para STEMI en el seguimiento a dos años

El stent de strut ultrafino de BIOTRONIK, Orsiro, ha demostrado ser superior al DES Xience en cuanto al fallo de la lesión tratada (TLF) a los 24 meses según los nuevos datos del seguimiento del
15
March
2021
| 14:42 Europe/Amsterdam

Superiority of Orsiro DES Over Xience DES Confirmed in STEMI Patients

In the BIOSTEMI clinical trial, powered for superiority, Orsiro is confirmed as the superior drug-eluting stent (DES) for STEMI at two-year follow-up

BIOTRONIK’s ultrathin-strut stent, Orsiro, demonstrated superiority over Xience DES for target lesion failure (TLF) at 24 months, according to new follow-up data from the BIOSTEMI trial.The latest
06
May
2020
| 09:24 Europe/Amsterdam
According to recently presented TICO trial data, patients with acute coronary syndrome (ACS) treated with BIOTRONIK’s Orsiro drug eluting stent (DES) benefit from stopping aspirin three months after
24
February
2020
| 00:00 Europe/Amsterdam

BIOTRONIK’s Ultrathin Strut Orsiro Coronary Drug-Eluting Stent Continues to Deliver Excellent Results After Three Years

Data from BIOFLOW-V Trial Presented at CRT and Published in JACC: Cardiovascular Interventions Reinforces Orsiro’s Ability to Outperform Abbott’s Xience

BIOTRONIK today announced three-year data from the BIOFLOW-V trial, which was presented yesterday at the 2020 CRT Congress. The three-year follow-up data demonstrates consistently lower clinical
21
February
2020
| 14:11 Europe/Amsterdam

BIOTRONIK Introduces Next Generation Drug-Eluting Stent System in the CE Region

Orsiro Mission Provides the Next Level of Deliverability for the Orsiro Stent

BIOTRONIK has announced CE Mark certification for the Orsiro Mission drug-eluting stent (DES) system. The next generation of the company’s ultrathin strut Orsiro DES provides higher deliverability
30
October
2019
| 00:00 Europe/Amsterdam

Orsiro Coronary Drug-Eluting Stent Receives Market Approval in China

BIOTRONIK’s Ultrathin-Strut Drug-Eluting Stent Soon Available in China Following Market Approval

BIOTRONIK announced today that its Orsiro coronary drug-eluting stent (DES) has been approved for sale in China by the National Medical Products Administration. The company expects to make the device